TBI:NYSETrueBlue, Inc. Analysis

TrueBlue, Inc. (TBI) is trading around $5.92, comfortably above its 20‑day SMA of $5.65 and its 200‑day SMA of $5.04, yet the MACD histogram is negative and the signal line is bearish, suggesting short‑term downside pressure. Volume is decreasing and the 30‑day volatility is high at roughly 63%, indicating a choppy market environment. The stock’s RSI sits at 65, below overbought levels but still in the upper range, reflecting lingering buying interest. Fundamentals are mixed: revenue grew 7.6% YoY to $1.64 B and beat estimates, but the company posted a Q1 loss of $19.8 M with negative operating and profit margins, and cash flow remains negative. Forward earnings are projected at $0.62 giving a forward PE of about 9.5, well below the industry average PE of 30, while the price‑to‑book of 0.65 and price‑to‑sales of 0.11 suggest a deep discount to book and sales. The upside potential metric points to a 44% upside, and the Fear & Greed Index is in “Extreme Greed” territory, indicating strong market optimism despite the weak earnings. The balance sheet shows modest cash ($24 M) against $130 M of debt, and a debt‑to‑equity of roughly 51%, raising concerns about financial flexibility. Overall, the stock appears undervalued on valuation multiples but carries significant execution risk given the loss streak and cash burn. Investors should weigh the attractive valuation against the operational challenges and heightened volatility before deciding.